Beta: Sign in
Shares outstandingAs of 2026-07-29 · filed common shares: 128.35M
Shares float: Sign in
Float %: Sign in
Insider ownershipDirectors and officers, from their latest Form 3/4/5 holding: 0.45%
Institutional ownership: Sign in
Short interestShare of shares outstanding, at settlement: 5.81%
Short ratioDays to cover, as published by FINRA: 3.74
Short volume (5D)Share of FINRA reporting-facility volume sold short, daily flow: 79.20%
Short volume (20D)Share of FINRA reporting-facility volume sold short, daily flow: 66.60%
Avg volume (10D)

See the full stock page

Prices, charts, ranges, valuation ratios, dividends, momentum and analyst estimates are licensed for signed-in members. A free account opens every stock, fund and crypto page.

Create free account

Source: SEC filings. Information and analytics, not investment advice.

Loading evidence for GENB

Avg volume (3 months)

Profitability

Gross margin: —
Operating margin (quarter)Quarter: 2026-04-01 to 2026-06-30 · Not annualized: -1134.21%
Net margin: —
EBITDA margin (quarter)Quarter: 2026-04-01 to 2026-06-30 · Not annualized: -1083.53%
Return on equity: —
Return on assets: —

Growth

Revenue growth (annual YoY): —
Revenue growth (latest qtr YoY): -37.67%
Revenue growth (fwd): Sign in
Net income growth (annual YoY): —
Net income growth (latest qtr YoY): —
EPS growth (fwd): Sign in
Net income growth (QoQ): —

Valuation

Market cap: Sign in
Enterprise value: Sign in
P/E: Sign in
P/E (fwd): Sign in
PEG: Sign in
PEG (fwd): Sign in
Price / book: Sign in
Price / sales: Sign in
Price / operating cash flow: Sign in
P/FCF: Sign in
EV / revenue: Sign in
EV / EBITDA: Sign in
EPS (diluted, quarter)Quarter: 2026-04-01 to 2026-06-30 · Not annualized: -0.52
EPS (fwd): Sign in

Financial health

Cash & equivalentsas of Jun 26: $135.35M
Total cash: Sign in
Total debtBorrowings + finance and operating lease liabilities, as of Jun 26: $62.62M
Debt / equityas of Jun 26: 13.73%
Current ratioas of Jun 26: 8.30
Quick ratio: —
Operating cash flow (six months)Six months: 2026-01-01 to 2026-06-30 · Not annualized: -$138.33M
Free cash flow (six months)Six months: 2026-01-01 to 2026-06-30 · Not annualized: -$143.04M
TTM revenue / diluted share: —

GENB stock Statistics — Generate Biomedicines, Inc. filings, insiders & smart money · Instaport